BioModelsapplication/xmlhttps://www.ebi.ac.uk/biomodels/model/download/BIOMD0000000748?filename=Phan2017.xmlhttps://www.ebi.ac.uk/biomodels/model/download/BIOMD0000000748?filename=Phan2017.cpshttps://www.ebi.ac.uk/biomodels/model/download/BIOMD0000000748?filename=Fig.2'.pnghttps://www.ebi.ac.uk/biomodels/model/download/BIOMD0000000748?filename=Phan2017.sedmlprimaryOK200Jinghao MenManually curatedordinary differential equation modelL3V1Immuno-oncologyhttps://www.ebi.ac.uk/biomodels/BIOMD000000074829379572falseBioModelsModelsSBMLPhan2017 innate immune in oncolytic virotherapy2017MODEL1907110001Phan TAPhan TA, Tian JP29379572,
The complexity of the immune responses is a major challenge in current virotherapy. This study incorporates the innate immune response into our basic model for virotherapy and investigates how the innate immunity affects the outcome of virotherapy. The viral therapeutic dynamics is largely determined by the viral burst size, relative innate immune killing rate, and relative innate immunity decay rate. The innate immunity may complicate virotherapy in the way of creating more equilibria when the viral burst size is not too big, while the dynamics is similar to the system without innate immunity when the viral burst size is big.. null, 2017.
Department of Mathematical Sciences, New Mexico State University, Las Cruces, NM 88001, USA.jm2187@cam.ac.ukUniversity of CambridgeBIOMD0000000748The complexity of the immune responses is a major challenge in current virotherapy. This study incorporates the innate immune response into our basic model for virotherapy and investigates how the innate immunity affects the outcome of virotherapy. The viral therapeutic dynamics is largely determined by the viral burst size, relative innate immune killing rate, and relative innate immunity decay rate. The innate immunity may complicate virotherapy in the way of creating more equilibria when the viral burst size is not too big, while the dynamics is similar to the system without innate immunity when the viral burst size is big.The Role of the Innate Immune System in Oncolytic Virotherapy.Phan Tuan Anh TA, Tian Jianjun Paul JPTherapies, Virotherapies, Therapy, Virus Therapy, Oncolytic Virus, Oncolytic Virotherapies., Virotherapy, Oncolytic Virus Therapies, Oncolytic, Virus Therapies, Oncolytic Virus Therapybig, study, proportion, AA408785, Immune Responses, euthanisia, AA960360., Native Immunity, anatomical systems, Innate Immunity, Natural Immunity, Natural, Immunity, nonspecific immune response, AA960360, Native, life termination, proportionality, expanded, innate immunity, rate, Big-3, Innate Immune Responses, Natural Resistance, body system, Non-Specific Immunity, death status type, Innate Immune Response, organ system, Big, large, Immune Response, sacrifice, enlarged, Non-Specific, great, Resistance, quotient, system, connected anatomical system, Innate, Non Specific, 2410008O07Rik, burst, ratioextent, big, euthanisia, Sectors, Innate Immunity, Public Sectors, Immune Systems, Procedures, Multiple myeloma (disorder), Kahler's disease, nonspecific immune response, Cell Myelomas, number, Copyrights, Myeloma-Multiples, Myeloma-Multiple, body system, presence, plasma cell, Medical Specialties, Speciality, Multiple Myelomas, Techniques, large, Medical Specialities, myelomatosis, Roles, Method, Specialities, myeloid neoplasm of plasma cell, BC031509, [M]Plasma cell myeloma, Myelomatoses, Studies, Concepts, system, Public Enterprise, Medical, 2410008O07Rik, Enterprises, Technique, Oncolytic Virus Therapy, Plasmacytic myeloma, systemic, study, amyloidosis, proportion, Immune Responses, Insurance Medicine, anatomical systems, Multiple myeloma, Natural, Paul, HOIP, AA960360, Somatic mutation, Plasma Cell Myelomas, Public Domains, myeloma, Big-3, procedures, Innate Immune Responses, Public Enterprises, Non-Specific Immunity, Study, drugs, resistance to, Immune, Abstract, Immune Response, Cell Myeloma, Methodological Studies, no ICD-O subtype (morphologic abnormality), medicine, Oncolytic, PAUL, great, Role Concepts, Therapies, Medicine, plasma cell myeloma, AL033293, Medicines, Insurance, Enterprise, Plasma Cell, Non Specific, myeloma - multiple, ratio, Plasma-Cell Myelomas, Plasma-cell myeloma, Virotherapies, Therapy, Disease, Specialties, Oncolytic Virus, Virotherapy, Natural Immunity, Papers, Myelomas, Medical Specialty, completeness, Myeloma, malignant, 6.3.2.-, Immunity, Flj10111, Native, mFLJ00217, life termination, innate immunity, Myeloma Multiple, Procedure, HOIL-1-interacting protein, Multiple Myeloma, death status type, MM, Concept, Al amyloidosis, multiple myeloma, Medical Speciality, Kahler, count in organism, Role Concept, Oncolytic Virus Therapies, sacrifice, Public, Public Domain, Systems, Oncolytic Virotherapies, Role, Specialty, Resistance, Domains, NOS, Myelomatosis, multiple myeloma/plasma cell myeloma, Putative Ariadne-like ubiquitin ligase, techniques, connected anatomical system, MULT MYELM W/O REMISSION, burst, morphology (morphologic abnormality), Domain, Plasma-Cell, Plasma-Cell Myeloma, Data Base, Plasma, AA408785, Native Immunity, RING finger protein 31, System, susceptibility to, proportionality, expanded, Kahler Disease, rate, Methodological, Natural Resistance, Methodological Study, medullary plasmacytoma, Virus Therapies, Multiple myeloma without mention of remission, Innate Immune Response, organ system, Big, Insurance Medicines, Multiple, Sector, no ICD-O subtype, multiple, Plasma Cell Myeloma, enlarged, Non-Specific, quotient, Virus Therapy, Public., Multiple myeloma (clinical), quantitative, Innate, Kahler disease, plasma cell myeloid neoplasm, methodology, presence or absence in organismConcept, Virotherapies, Therapy, Immune, Oncolytic Virus, Role Concept, Virotherapy, Immune Systems, Oncolytic Virus Therapies, Roles, Oncolytic, Role Concepts, System, Systems, Role, Therapies, Concepts, Virus Therapy, Oncolytic Virotherapies., Virus Therapies, Oncolytic Virus TherapyfalsePhan2017 - innate immune in oncolytic virotherapyThe paper describes a model on the key components for tumor–immune dynamics in multiple myeloma.
Created by COPASI 4.25 (Build 207)
This model is described in the article:
The Role of the Innate Immune System in Oncolytic Virotherapy
Tuan Anh Phan and Jianjun Paul Tian
Computational and Mathematical Methods in Medicine (2017) 6587258
Abstract:
The complexity of the immune responses is a major challenge in current virotherapy. This study incorporates the innate immune response into our basic model for virotherapy and investigates how the innate immunity affects the outcome of virotherapy. The viral therapeutic dynamics is largely determined by the viral burst size, relative innate immune killing rate, and relative innate immunity decay rate. The innate immunity may complicate virotherapy in the way of creating more equilibria when the viral burst size is not too big, while the dynamics is similar to the system without innate immunity when the viral burst size is big.
To cite BioModels Database, please use: BioModels Database: An enhanced, curated and annotated resource for published quantitative kinetic models .
To the extent possible under law, all copyright and related or neighbouring rights to this encoded model have been dedicated to the public domain worldwide.
Please refer to CC0 Public Domain Dedication for more information.2019-07-112019-07-112019-07-11BIOMD0000000748SBO:0000393SBO:0000610SBO:000017929379572C94498C94967C62713C717C28241C94345C3439BIOMD0000000748MODEL1907110001GO:0008219GO:0019058GO:0008283GO:0002418GO:0006955GO:0070661CL:00010639606